Early treatment: PreCISe-ly what the patient needs

Journal of the Neurological Sciences

Volumn 287, Issue SUPPL. 1, 2009, Pages

  Montalban, Xavier ^a  

^a HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

Author keywords

Disability; Glatiramer acetate; interferon ; MRI; Multiple sclerosis; Natural history

Indexed keywords

BETA1A INTERFERON; GADOLINIUM; GLATIRAMER; INTERFERON BETA SERINE; PLACEBO;

ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; DEPRESSION; DRUG SAFETY; HISTOPATHOLOGY; HUMAN; IMMUNOMODULATION; INJECTION SITE REACTION; MULTIPLE SCLEROSIS; NUCLEAR MAGNETIC RESONANCE IMAGING; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; PATIENT MONITORING; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RELAPSE; SUICIDE; UNSPECIFIED SIDE EFFECT;

ALGORITHMS; BRAIN; DEMYELINATING DISEASES; DISEASE PROGRESSION; HUMANS; IMMUNOSUPPRESSIVE AGENTS; MAGNETIC RESONANCE IMAGING; MULTICENTER STUDIES AS TOPIC; MULTIPLE SCLEROSIS; PEPTIDES; PRACTICE GUIDELINES AS TOPIC; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SEVERITY OF ILLNESS INDEX; SPINAL CORD; TIME FACTORS; TREATMENT OUTCOME;

EID: 72649104482     PISSN: 0022510X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0022-510X(09)71293-6     Document Type: Article

References (33)

1. McDonald W.I., Compston A., Edan G., Goodkin D., Hartung H.P., Lublin F.D., et al. Recommended diagnostic criteria for multiple sclerosis: guidelines from the International Panel on the diagnosis of multiple sclerosis. Ann Neurol 50 (2001) 121-127
2. Polman C.H., Reingold S.C., Edan G., Filippi M., Hartung H.P., Kappos L., et al. Diagnostic criteria for multiple sclerosis: 2005 revisions to the "McDonald Criteria". Ann Neurol 58 (2005) 840-846
3. Poser C.M., Paty D.W., Scheinberg L., McDonald W.I., Davis F.A., Ebers G.C., et al. New diagnostic criteria for multiple sclerosis: guidelines for research protocols. Ann Neurol 13 (1983) 227-231
4. Rovira A., Swanton J., Tintoré M., Huerga E., Barkhof F., Filippi M., et al. A single, early magnetic resonance imaging study in the diagnosis of multiple sclerosis. Arch Neurol 66 (2009) 587-592
5. Montalban X, Tintoré M, Swanton J, Barkhof F, Fazekas F, Filippi M, et al. MRI criteria for MS in patients with clinically isolated syndromes. Neurology (in press).
6. Jacobs L.D., Beck R.W., Simon J.H., Kinkel R.P., Brownscheidle C.M., Murray T.J., et al. Intramuscular interferon beta-1a therapy initiated during a first demyelinating event in multiple sclerosis. CHAMPS Study Group. N Engl J Med 343 (2000) 898-904
7. Comi G., Filippi M., Barkhof F., Durelli L., Edan G., Fernandez O., et al. Effect of early interferon treatment on conversion to definite multiple sclerosis: a randomised study. Lancet 357 (2001) 1576-1582
8. Comi G., Martinelli V., Rodegher M., Moiola L., Bajenaru O., Carra A., et al. Effect of glatiramer acetate on conversion to clinically definite multiple sclerosis in patients with clinically isolated syndrome (PreCISe study): a randomised, double-blind, placebo-controlled trial. Lancet 374 (2009) 1503-1511
9. Kappos L., Polman C.H., Freedman M.S., Edan G., Hartung H.P., Miller D.H., et al. Treatment with interferon beta-1b delays conversion to clinically definite and McDonald MS in patients with clinically isolated syndromes. Neurology 67 (2006) 1242-1249
10. Weinshenker B.G., Rice G.P., Noseworthy J.H., Carriere W., Baskerville J., and Ebers G.C. The natural history of multiple sclerosis: a geographically based study.3. Multivariate analysis of predictive factors and models of outcome. Brain 114 Pt 2 (1991) 1045-1056
11. Langer-Gould A., Popat R.A., Huang S.M., Cobb K., Fontoura P., Gould M.K., et al. Clinical and demographic predictors of long-term disability in patients with relapsing-remitting multiple sclerosis: a systematic review. Arch Neurol 63 (2006) 1686-1691
12. Brex P.A., Jenkins R., Fox N.C., Crum W.R., O'Riordan J.I., Plant G.T., et al. Detection of ventricular enlargement in patients at the earliest clinical stage of MS. Neurology 54 (2000) 1689-1691
13. Paolillo A., Piattella M.C., Pantano P., Di Legge S., Caramia F., Russo P., et al. The relationship between inflammation and atrophy in clinically isolated syndromes suggestive of multiple sclerosis: a monthly MRI study after triple-dose gadolinium-DTPA. J Neurol 251 (2004) 432-439
14. Dalton C.M., Chard D.T., Davies G.R., Miszkiel K.A., Altmann D.R., Fernando K., et al. Early development of multiple sclerosis is associated with progressive grey matter atrophy in patients presenting with clinically isolated syndromes. Brain 127 (2004) 1101-1107
15. De Stefano N., Matthews P.M., Filippi M., Agosta F., De Luca M., Bartolozzi M.L., et al. Evidence of early cortical atrophy in MS: relevance to white matter changes and disability. Neurology 60 (2003) 1157-1162
16. Brex P.A., Leary S.M., O'Riordan J.I., Miszkiel K.A., Plant G.T., Thompson A.J., et al. Measurement of spinal cord area in clinically isolated syndromes suggestive of multiple sclerosis. J Neurol Neurosurg Psychiatry 70 (2001) 544-547
17. Rashid W., Davies G.R., Chard D.T., Griffin C.M., Altmann D.R., Gordon R., et al. Increasing cord atrophy in early relapsing-remitting multiple sclerosis:a3year study. J Neurol Neurosurg Psychiatry 77 (2006) 51-55
18. Filippi M., Bozzali M., Rovaris M., Gonen O., Kesavadas C., Ghezzi A., et al. Evidence for widespread axonal damage at the earliest clinical stage of multiple sclerosis. Brain 126 (2003) 433-437
19. De Stefano N., Narayanan S., Francis G.S., Arnaoutelis R., Tartaglia M.C., Antel J.P., et al. Evidence of axonal damage in the early stages of multiple sclerosis and its relevance to disability. Arch Neurol 58 (2001) 65-70
20. Ferguson B., Matyszak M.K., Esiri M.M., and Perry V.H. Axonal damage in acute multiple sclerosis lesions. Brain 120 Pt 3 (1997) 393-399
21. Trapp B.D., Peterson J., Ransohoff R.M., Rudick R., Mork S., and Bo L. Axonal transection in the lesions of multiple sclerosis. N Engl J Med 338 (1998) 278-285
22. Kuhlmann T., Lingfeld G., Bitsch A., Schuchardt J., and Bruck W. Acute axonal damage in multiple sclerosis is most extensive in early disease stages and decreases over time. Brain 125 (2002) 2202-2212
23. Trapp B.D., Bo L., Mork S., and Chang A. Pathogenesis of tissue injury in MS lesions. J Neuroimmunol 98 (1999) 49-56
24. Jacobs L.D., Cookfair D.L., Rudick R.A., Herndon R.M., Richert J.R., Salazar A.M., et al. Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis. The Multiple Sclerosis Collaborative Research Group (MSCRG). Ann Neurol 39 (1996) 285-294
25. Johnson K.P., Brooks B.R., Cohen J.A., Ford C.C., Goldstein J., Lisak R.P., et al. Copolymer 1 reduces relapse rate and improves disability in relapsing-remitting multiple sclerosis: results of a phase III multicenter, double-blind placebo-controlled trial. The Copolymer 1 Multiple Sclerosis Study Group. Neurology 45 (1995) 1268-1276
26. PRISMS (Prevention of Relapses and Disability by Interferon beta-1a Subcutaneously in Multiple Sclerosis) Study Group. Randomised double-blind placebo-controlled study of interferon beta-1a in relapsing/remitting multiple sclerosis. Lancet 352 (1998) 1498-1504
27. The IFNB Multiple Sclerosis Study Group and The University of British Columbia MS/MRI Analysis Group. Interferon beta-1b in the treatment of multiple sclerosis: final outcome of the randomized controlled trial. Neurology 45 (1995) 1277-1285
28. European Study Group on interferon beta-1b in secondary progressive MS. Placebo-controlled multicentre randomised trial of interferon beta-1b in treatment of secondary progressive multiple sclerosis. Lancet 352 (1998) 1491-1497
29. Cohen J.A., Cutter G.R., Fischer J.S., Goodman A.D., Heidenreich F.R., Kooijmans M.F., et al. Benefit of interferon beta-1a on MSFC progression in secondary progressive MS. Neurology 59 (2002) 679-687
30. Panitch H., Miller A., Paty D., and Weinshenker B. Interferon beta-1b in secondary progressive MS: results from a 3-year controlled study. Neurology 63 (2004) 1788-1795
31. Andersen O., Elovaara I., Farkkila M., Hansen H.J., Mellgren S.I., Myhr K.M., et al. Multicentre, randomised, double blind, placebo controlled, phase III study of weekly, low dose, subcutaneous interferon beta-1a in secondary progressive multiple sclerosis. J Neurol Neurosurg Psychiatry 75 (2004) 706-710
32. SPECTRIMS Study Group. Randomized controlled trial of interferon-beta-1a in secondary progressive MS: Clinical results. Neurology 56 (2001) 1496-1504
33. Arnold D., Narayanan S., and Antel S. Treatment with glatiramer acetate protects axons in patients with clinically isolated syndromes: evidence from the PreCISe trial. Mult Scler 14 (2008) S10